ICU Medical (ICUI)
(Delayed Data from NSDQ)
$95.88 USD
-0.45 (-0.47%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $95.86 -0.02 (-0.02%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Income Statements
Fiscal Year end for ICU Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,259 | 2,280 | 1,316 | 1,271 | 1,266 |
Cost Of Goods | 1,519 | 1,582 | 825 | 810 | 794 |
Gross Profit | 740 | 698 | 491 | 462 | 472 |
Selling & Adminstrative & Depr. & Amort Expenses | 717 | 741 | 368 | 363 | 365 |
Income After Depreciation & Amortization | 23 | -43 | 123 | 98 | 107 |
Non-Operating Income | -6 | -5 | 1 | 1 | 8 |
Interest Expense | 95 | 66 | 1 | 2 | 1 |
Pretax Income | -78 | -114 | 123 | 97 | 115 |
Income Taxes | -49 | -40 | 20 | 11 | 14 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -74 | 103 | 87 | 101 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -74 | 103 | 87 | 101 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 258 | 226 | 214 | 193 | 193 |
Depreciation & Amortization (Cash Flow) | 236 | 269 | 91 | 95 | 86 |
Income After Depreciation & Amortization | 23 | -43 | 123 | 98 | 107 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 24.09 | 23.87 | 21.78 | 21.59 | 21.55 |
Diluted EPS Before Non-Recurring Items | 5.50 | 5.27 | 6.13 | 6.13 | 7.36 |
Diluted Net EPS (GAAP) | -1.23 | -3.11 | 4.74 | 4.02 | 4.69 |
Fiscal Year end for ICU Medical, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 587.86 | 553.31 | 549.31 | 568.65 |
Cost Of Goods | NA | 416.27 | 369.39 | 356.98 | 376.61 |
Gross Profit | NA | 171.58 | 183.92 | 192.33 | 192.04 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 183.77 | 161.07 | 189.57 | 182.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -12.19 | 22.85 | 2.76 | 9.39 |
Non-Operating Income | NA | -0.09 | -4.04 | -1.50 | -0.27 |
Interest Expense | NA | 24.41 | 24.18 | 24.12 | 22.52 |
Pretax Income | NA | -36.68 | -5.37 | -22.86 | -13.39 |
Income Taxes | NA | -19.53 | -12.60 | -12.93 | -3.58 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.15 | 7.24 | -9.93 | -9.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -17.15 | 7.24 | -9.93 | -9.81 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 24.14 | 24.37 | 24.08 | 24.01 |
Diluted EPS Before Non-Recurring Items | NA | 1.24 | 1.23 | 1.58 | 1.45 |
Diluted Net EPS (GAAP) | NA | -0.71 | 0.30 | -0.41 | -0.41 |